In this Community Case Forum series, experts and participants discuss the evolving landscape of second-line treatment for patients with HR+, HER2- metastatic breast cancer.
Tailoring Second-Line Treatments for HR-Positive, HER2-Negative Metastatic Breast Cancer
With several options available for the second-line treatment of HR-positive, HER2-negative mBC, an expert emphasized the importance of tailoring treatment for every patient.
Understanding the Mechanism of Action Behind PARP Inhibitors for Prostate Cancer
Tools to Monitor for ICANS During Lymphoma Treatment With Bispecific Antibodies, CAR T-Cell Therapy
‘Bringing Every Single Resource’ When Caring for Patients Receiving Treatment for Gynecologic Cancers
Bringing DEI to Clinical Trial, Cancer Clinics Through Self-Awareness